Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Nov;4(4):509-14.

Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation

Affiliations
  • PMID: 16286253
Review

Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation

Zi-Fa Wang et al. Hepatobiliary Pancreat Dis Int. 2005 Nov.

Abstract

Background: In the 1990s, liver transplantation for hepatitis B virus (HBV) related-liver diseases was a very controversial issue because the graft was inevitably recurrent after liver transplantation. Significant progress has been made in the prophylaxis and treatment of recurrent hepatitis B after liver transplantation. This review covers the mechanisms, prophylaxis, and treatment of hepatitis B recurrent after liver transplantation.

Data sources: Searching MEDLINE (1995-2004) for articles on liver transplantation.

Results: HBV reinfection after liver transplantation results from HBV particles in circulation or other extrahepatic sites. Hepatitis B immune globulin (HBIG) was effective in reducing HBV reinfection and improving graft survival after liver transplantation. Lamivudine has also dramatically reduced the recurrence of HBV in the patient undergoing liver transplantation.

Conclusions: Combination HBIG and lamivudine is the most effective porphylatic regimen. Lamivudine and adefovir are highly effective in treatment of HBV recurrence. HBV-related liver disease is no longer a contraindication for liver transplantation.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources